期刊
LEUKEMIA RESEARCH
卷 37, 期 7, 页码 795-801出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2013.03.001
关键词
Acute promyelocytic leukemia; All-trans retinoic acid; Late relapse
资金
- Public Health Service Grant [CA21115, CA23318, CA66636, CA17145, CA14958, CA77658, CA32102, CA 37027, CA12213]
- National Cancer Institute, National Institutes of Health
- Department of Health and Human Services
- [CA021115]
- [CA114737]
- [CA56771]
We report a long-term follow-up (median 11.8 years) of the First North American Intergroup Study. 379 patients were randomized to induction with ATRA or to chemotherapy. All complete responders (CR) received consolidation chemotherapy, then randomized to 1 year ATRA or observation. 245 patients received ATRA sometime during the study: 195 (80%) achieved a CR. Nine (4.6%) relapsed late (>3 years from CR), the last occurred after 4.6 years; 7 of them were still alive after 5.5-15 years. In APL patients, late relapses are uncommon, and those who sustain CR >5 years can be considered cured. (C) 2013 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据